Jordan J. Lancaster

Jordan J. Lancaster

Auto-generated profile, based on publicly available information

Jordan J. Lancaster

Sarver Heart Center, University of Arizona, Tucson, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2017 in Stem Cells International
Verified
Journal Article
Open access
PDF file
APAmitabh C. Pandey
Amitabh C. Pandey
JLJordan J. Lancaster
Jordan J. Lancaster
DHDavid T. Harris
David T. Harris
SGSteven Goldman
Steven Goldman
EJElizabeth Juneman
Elizabeth Juneman
Resulting from a various etiologies, the most notable remains ischemia; heart failure (HF) manifests as the common end pathway of many cardiovascular processes and remains among the top causes for hospitalization and a major cause of morbidity and mortality worldwide. Current pharmacologic treatment for HF utilizes pharmacologic agents to control symptoms and slow further deterioration; however, on a cellular level, in a patient with progressive disease, fibrosis and cardiac remodeling can continue leading to end-stage heart failure. Cellular therapeutics have risen as the new hope for an improvement in the treatment of HF. Mesenchymal stem cells (MSCs) have gained popularity given their propensity of promoting endogenous cellular repair of a myriad of disease processes via paracrine signaling through expression of various cytokines, chemokines, and adhesion molecules resulting in activation of signal transduction pathways. While the exact mechanism remains to be completely elucidated, this remains the primary mechanism identified to date. Recently, MSCs have been incorporated as the central focus in clinical trials investigating the role how MSCs can play in the treatment of HF. In this review, we focus on the characteristics of MSCs that give them a distinct edge as cellular therapeutics and present results of clinical trials investigating MSCs in the setting of ischemic HF.

8 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CMCraig C. Morris
Craig C. Morris
JRJacob Ref
Jacob Ref
SASatya Acharya
Satya Acharya
KJKevin J. Johnson
Kevin J. Johnson
SSScott Squire
Scott Squire
RARyan Avery
Ryan Avery
In swine models, there are well-established protocols for creating a closed-chest myocardial infarction (MI) as well as protocols for characterization of cardiac function with cardiac magnetic resonance (CMR). This methods manuscript outlines a novel technique in CMR data acquisition utilizing smart-signal gradient recalled echo (GRE)-based array sequences in a free-breathing swine heart failure model allowing for both high spatial and temporal resolution imaging. Nine male Yucatan mini swine weighing 48.7 ± 1.6 kg at 58.2 ± 3.1 weeks old underwent the outlined imaging protocol before and 1-month after undergoing closed chest left anterior descending coronary artery (LAD) occlusion/reperfusion. The left ventricular ejection fraction (LVEF) at baseline was 59.3 ± 2.4% and decreased to 48.1 ± 3.7% 1-month post MI (P = 0.029). The average end-diastolic volume (EDV) at baseline was 55.2 ± 1.7 ml and increased to 74.2 ± 4.2 ml at 1-month post MI (P = 0.001). The resulting images from this novel technique and post-imaging analysis are presented and discussed. In a Yucatan swine model of heart failure via closed chest left anterior descending coronary artery (LAD) occlusion/reperfusion, we found that CMR with GRE-based array sequences produced clinical-grade images with high spatial and temporal resolution in the free-breathing setting.

17 September 2019 in Vessel Plus
Verified
Journal Article
Open access
PDF file
JLJordan J. Lancaster
Jordan J. Lancaster
JKJen Watson Koevary
Jen Watson Koevary
ICIkeotunye Royal Chinyere
Ikeotunye Royal Chinyere
SDSherry L. Daugherty
Sherry L. Daugherty
KFKenneth A. Fox
Kenneth A. Fox
SGSteven Goldman
Steven Goldman
Vessel Plus is an open acccess journal, which publishes articles related to vascular diseases, including acute respiratory distress syndrome, aneurysm, atherosclerosis, hypertension, stroke, peripheral vascular or pulmonary vascular diseases, etc.

1 August 2017 in Journal of Cardiac Failure
Verified
Journal Article
Open access
JLJordan J. Lancaster
Jordan J. Lancaster
JKJen Koevary
Jen Koevary
ICIkeotunye Royal Chinyere
Ikeotunye Royal Chinyere
EJElizabeth Juneman
Elizabeth Juneman
SGSteven Goldman
Steven Goldman

1 August 2012 in Journal of Cardiac Failure
Verified
Journal Article
Open access
EJElizabeth Juneman
Elizabeth Juneman
JLJordan Lancaster
Jordan Lancaster
RWRussell Witte
Russell Witte
JBJoseph Bahl
Joseph Bahl
SGSteven Goldman
Steven Goldman